On June 13, 2014 EntreMed, Inc. ENMD, a clinical-stage biopharmaceutical company developing therapeutics for the treatment of cancer and other diseases, reported that at its annual meeting of stockholders held on June 12, 2014, stockholders voted in favor of changing the company’s corporate name to CASI Pharmaceuticals, Inc (Press release, EntreMed, JUN 13, 2014, View Source [SID:1234512362]). The name change will occur on June 16, 2014 with the Company’s common stock trading on NASDAQ under the new symbol "CASI" and the rollout of a new website www.casipharmaceuticals.com.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Changing our name is an important milestone as it represents another step toward completing our company’s transformation," said Ken K. Ren, Ph.D., EntreMed’s chief executive officer. "Our operations and strategic focus have evolved and today have little resemblance to our legacy years. Our name change is another step towards our mission to build a new and leading biopharmaceutical company targeting global markets with a focus on China."
About ENMD-2076
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases, which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase I clinical trials in solid tumor cancers including ovarian, breast, liver, renal and sarcoma, as well as in leukemia and multiple myeloma. EntreMed is completing a Phase II trial of ENMD-2076 in ovarian cancer. In addition, EntreMed is conducting a dual-institutional Phase II study of ENMD-2076 in triple-negative breast cancer, a Phase II study in advanced/metastatic soft tissue sarcoma and a Phase II study in advanced ovarian clear cell carcinomas. ENMD-2076 has received orphan drug designation from the U.S. FDA for the treatment of ovarian cancer, multiple myeloma and acute myeloid leukemia.